NCT04674449 iCorMicA - Stratified Medicine in Angina
| NCT ID | NCT04674449 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NHS Greater Glasgow and Clyde |
| Condition | Microvascular Angina |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2020-12-30 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,500 participants in total. It began in 2020-12-30 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The iCorMicA study is a multicentre, prospective, randomised, double-blind, sham-controlled, parallel-group, end-point trial and registry. The investigators seek to determine whether stratified medical therapy guided by an adjunctive interventional diagnostic procedure (IDP) during the invasive management of patients with known or suspected angina but no obstructive coronary artery disease improves symptoms, wellbeing, cardiovascular risk and clinical outcomes.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years. 2. A clinical plan for invasive coronary angiography. 3. Symptoms of angina (typical or atypical) according to the Rose- and/or Seattle Angina questionnaires. 4. Able to comply with study procedures. 5. Able to provide informed consent. Exclusion Criteria: 1. A non-coronary primary indication for invasive angiography (e.g. valve disease, heart failure). 2. History of coronary artery bypass surgery. 3. Presence of obstructive disease evident in a main coronary artery (diameter \>2.5 mm), i.e. a coronary stenosis \>50% and/or a fractional flow reserve (FFR) ≤0.80\*. 4. Logistical reason\*. \*These patients will enter a follow-up registry.
Contact & Investigator
Colin Berry, MBChB, PhD
STUDY CHAIR
University of Glasgow
Frequently Asked Questions
Who can join the NCT04674449 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Microvascular Angina. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04674449 currently recruiting?
Yes, NCT04674449 is actively recruiting participants. Contact the research team at colin.berry@glasgow.ac.uk for enrollment information.
Where is the NCT04674449 trial being conducted?
This trial is being conducted at Cork, Ireland, Dublin, Ireland, Nijmegen, Netherlands, Krakow, Poland and 11 additional locations.
Who is sponsoring the NCT04674449 clinical trial?
NCT04674449 is sponsored by NHS Greater Glasgow and Clyde. The principal investigator is Colin Berry, MBChB, PhD at University of Glasgow. The trial plans to enroll 1,500 participants.